Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic acquisition agreement with Shanghai-based biotech firm Curon Biopharmaceutical. Under the terms of the deal, MSD will fully acquire CN201, a cutting-edge CD3 x CD19-targeted T-cell-engager bispecific antibody (BsAb). The transaction includes an upfront payment of USD 700 million, with an additional USD 600 million earmarked for milestone payments tied to development and regulatory milestones. The acquisition grants MSD global rights to the molecule, with the deal expected to close in the third quarter of 2024.
CN201’s mechanism of action is similar to that of Amgen’s bispecific T-cell engager Blincyto (blinatumomab). It is currently undergoing evaluation in Phase I and Phase Ib/II clinical trials for the treatment of relapsed or refractory non-Hodgkin’s lymphoma and relapsed or refractory acute lymphocytic leukemia. MSD intends to explore CN201’s potential not only in treating B-cell malignancies but also as a candidate for autoimmune disease therapies.
Curon Biopharmaceutical, established in 2018, is a biotech startup incubated by 6 Dimensions Capital and has received substantial financial backing of USD 150 million from Boyu Capital and Temasek, highlighting its potential in the biopharmaceutical industry.- Flcube.com
